Nuformix

Activities: Research & Development

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Ingredients

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

The drug for treatment of multiple CNS conditions will be reformed into a novel patentable form to potentially improve delivery and give more intellectual property protection
Media

Quotient Clinical and Nuformix evaluate cocrystals with translational pharmaceutics

Quotient Clinical, provider of early stage and specialist drug development services, announced it has signed an agreement with Nuformix Technologies, to evaluate the clinical performance of Nuformix’s lead pharmaceutical cocrystal, NXP001, based on a currently marketed treatment in the field of oncology supportive care
Manufacturing

Onyx wins characterisation support contract

Will supply Nuformix with a stand-alone service
Subscribe now